Betha sudhakar biography of albert
•
Abstract
Objectives
To determine the efficacy of functional electrical stimulation therapy assisted walking (FES-T) compared to a conventional aerobic and resistance training (CONV) with respect to bone biomarkers and lower extremity bone strength outcomes among adults with chronic motor incomplete spinal cord injury (SCI).
Design
Parallel group randomized controlled trial ( - NCT).
Site
Tertiary academic rehabilitation centre in Canada.
Methods
Adults with chronic (≥18 months) motor incomplete SCI (C2-T12 AIS C-D) were consented and randomized to FES-T or CONV training for 45 minutes thrice-weekly for 4 months. Osteocalcin (OC), β-cross laps (CTX) and sclerostin were assessed at baseline, and 4 months. Similarly, total hip, distal femur and proximal tibia region bone mineral density (BMD) via DXA (A, Hologic Inc. Waltham, MA, USA) and tibia bone quality via pQCT (Stratec XCT, Mezintecknik, Pforzheim, Germany) were assessed at baseline, 4, and 12 months. Between group differ
•
The emergence of a novel human coronavirus recently renamed the mittpunkt East Respiratory Syndrome Coronavirus (MERS-CoV) from the Arabian Peninsula has created global alarm because it fryst vatten the causative agent of a severe and frequently fatal acute respiratory illness (SARI) resembling the illness caused bygd severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV).1–4 The case fatality rate (CFR) in patients infected with MERS-CoV fryst vatten high—estimated at 43% in patients reported so far by World Health Organization (WHO).3 This rate fryst vatten higher than that of SARS—estimated at 15%, and is strongly age- and sex-dependent.4 Although the source of virus in patients with sporadic infection remains unknown, it appears likely to be some species of animal.4,5 Clear bevis of limited human-to-human transmission of MERS-CoV has now been documented in several case clusters, including particularly family members and patients in health care facilities,6–8 but all such clu
•
Abstract
The significant rise in the number of diabetic patients worldwide, as well as the development of new insulin delivery techniques such as inhalation or oral administration which require higher dosages, are expected to increase the demand for recombinant insulin. Current manufacturing technologies will be unable to fulfill the rising demand for inexpensive insulin due to their production capacity limitations and high production costs. Production of therapeutic recombinant insulin requires a suitable host organism with adequate post-translational modification and refolding machinery. E. coli and S. cerevisiae have been used extensively to make recombinant human insulin for medicinal applications. However, transgenic plants are particularly appealing expression systems as they can be used to synthesize huge amounts of insulin for human medicinal purposes. Plant-based expression systems have the potential for high-capacity insulin synthesis at a minimal cost. The sign